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Epidemiology of congenital cerebral anomalies in Europe -a multi-centre, population-based EUROCAT study
INTRODUCTION
It is important to have background information about the epidemiology of congenital cerebral anomalies including associated anomalies and trends over time. This enables a knowledge-based evaluation of possible future changes in the prevalence and associated anomalies, which could be related to the occurrence of new teratogens. For example, Maternal Zika virus infection is acknowledged to increase the risk of microcephaly occurring in the fetus [1, 2] . However, there is more uncertainty as to the association of maternal Zika virus infections with other structural cerebral anomalies [3] .
EUROCAT)is a European network of population-based registries for the epidemiologic surveillance of congenital anomalies ( http://www.eurocat-network.eu/) [4, 5] . There are many EUROCAT publications on neural tube defects [6] [7] [8] , microcephaly [9] , hydrocephaly [10] and septo-optic dysplasia [11] . Individual EUROCAT registries have published data on corpus callosum anomalies in Emilia Romagna [12] , schizencephaly [13] and holoprosencephaly [14] in the UK. However, the epidemiology of these and other cerebral anomalies from the Q04 chapter in ICD10 such as reduction defects of the brain, microgyria, megalencephaly, cerebral cysts and schizencephaly have never been analysed at a European level and most of these anomalies are quite rare with little published epidemiological data. A previous EUROCAT collaboration with the Surveillance of Cerebral Palsy in Europe network has shown that the majority of congenital anomalies in children with cerebral palsy are cerebral anomalies [15, 16] , indicating the severity of the clinical outcome of these congenital anomalies.
Most cerebral anomalies are not recognised at birth, but may be diagnosed pre-and postnatally by ultrasound scans and other imaging examinations including magnetic resonance imaging (MRI). As diagnostic methods, prenatally and in the neonatal period, are known to vary over time, and between countries in Europe, and because some registries include late diagnosed cases up to five years of age or more, major European differences in the prevalence of cerebral anomalies are expected.
The aim of this study was to describe the epidemiology of specific congenital cerebral anomalies in Europe and the observed geographical differences in prevalence using EUROCAT data.
METHODS
The EUROCAT registries are population based; the geographically defined populations and the methodology of collecting individual case data for EUROCAT is described elsewhere [4] . other specified anomalies of brain (Q048) and unspecified congenital anomalies of brain (Q049). Some registries added the 4 th digit code from British Associations extension of ICD10 for Q043 for further specification (agyria/ lissenencephaly, microgyria/polygyria, hydranencephaly, reduction anomalies of cerebrum, reduction anomalies of cerebellum). A previous paper has reported data from the cases with septo-optic dysplasia [11] , which for completeness are also included in this paper. Not all registries contributed data for all 10 years. Data about each case included year of birth, type of birth, GA at birth or termination, infant sex, time of diagnosis, maternal age and associated congenital anomalies.
Classification of the congenital anomalies
Cases were classified as isolated cerebral anomalies, chromosomal cases, teratogenic or genetic syndromes or multiple congenital anomalies (anomalies from other organ systems plus a cerebral anomaly) according to the EUROCAT multiple congenital anomaly flowchart [18] and manual review of the written text description of the anomalies. Cases with additional codes and/or written text description of microcephaly, ventriculomegaly and hydrocephaly were classified as isolated cerebral anomalies. Combinations of cerebral anomalies within the Q04 chapter were classified hierarchically according to Table 2 so that all cases were allocated to one main cerebral anomaly diagnosis -diagnoses on the left taking precedence over those on the right. The diagnoses of single cerebral cyst, arachnoid and choroid plexus cysts and anomalies of septum pellucidum are on the EUROCAT list of minor anomalies for exclusion and these cases were therefore excluded, if described in the written text as the only cerebral anomaly. Cases with written text description of large cisterna magna, asymmetric ventricles or minor ventriculomegaly (<15 mm) were excluded if these were the only cerebral anomalies. Colpocephaly was classified as a secondary anomaly if associated with agenesis of corpus callosum. There are no specific ICD10 codes for the most frequent 6 cerebral syndromes (Joubert, Aicardi, Walker-Warburg and Miller-Dieker syndrome) and these are reported based on written text descriptions. There were no written text descriptions for cases from the registries in Paris and Norway and Northern England (NorCAS) used standard written text. Trends over time are presented as pan-European trends excluding genetic cases (chromosomal anomaly or genetic syndrome).
Method to Identify Under-reporting
A previous study of septo-optic dysplasia [11] found evidence that some registries were under-reporting cases and developed a method to estimate the prevalence adjusting for this under-reporting. In brief, for each separate anomaly, the average prevalence amongst the 15 registries with the highest prevalence is calculated using a random effects meta-analysis. The average prevalence of the whole population is then estimated by adjusting the prevalence observed in these 15 registries by factors to adjust for the fact that 
Statistical Analysis
The prevalence of the anomalies and the trends over time were investigated by fitting Poisson regression multi-level models with registry as a random effect. Associations between prevalence and prenatal diagnosis rates and the length of follow-up a registry performs (that is up to what age they still collect diagnoses classified into within 1 week, within 1 year and over 1 year) were investigated using Poisson regression with prenatal diagnosis and length of follow-up as covariates. All other exploratory analyses between anomalies were investigated using ANOVA and chi-squared tests according to whether the variable of interest was categorical or not.
RESULTS
The study included 4927 cases with a congenital cerebral anomaly giving an overall prevalence (adjusted for under-reporting) of 9.8 (95% CI: 8.5 to 11.2) per 10,000 births in the 29 registries. There were major differences in prevalence by registry (Table 1, Figure 1 ), with more than a six-fold difference between the registry with the lowest prevalence (South Portugal; 2.7 per 10,000) and the registry with the highest prevalence (French West Indies; 16.6 per 10,000). The proportions of cases that were diagnosed prenatally varied considerably between registries. There was an association between prevalence and the proportion of prenatal diagnoses; registries with higher proportions of prenatal diagnoses had a higher prevalence (p=0.029; Figure 2 ), but significant heterogeneity between registers still remained. There was no association between length of follow-up performed by the registry and the prevalence (p=0.5).
Congenital malformations of the corpus callosum and "other reduction deformities of the brain" were the most common cerebral anomalies, with an adjusted prevalence of 3.3 (95%CI 2.7 -3.8) and 2.9 (95%CI 2.5 -3.4) respectively. The adjusted prevalence of holoprosencephaly was 1.6 (95%CI: 1.4 -1.8) per 10,000 births and of megalencephaly was 0.08 (95%CI: 0.05 -0.11) per 10,000 births.
Overall 3448 cases were diagnosed prenatally (70% of the total, ranging from 50% to 94% amongst registries) and of these 2043 resulted in a TOPFA (59% of the prenatally diagnosed cases). The prenatal diagnosis may have occurred due to a different anomaly, we cannot distinguish which anomaly was diagnosed first . Overall 55% of cases were livebirths, 3% fetal deaths and 41% TOPFAs, with large variation between registries and cerebral anomaly. livebirthsPregnancies with septo-optic dysplasia were most likely to result in a live birth (96%) and pregnancies with arhinencephaly least likely to result in a live birth (4%). Overall, 28% of all livebirths were born preterm (GA < 37 weeks) which varied according to anomaly; babies with septo-optic dysplasia and megalencephaly were the least likely to be born preterm (19% and 17% respectively) ( Table 2 ).
The average maternal age for all cases of cerebral anomalies was 29.9 years. The mean maternal age was significantly lower in cases of septo-optic dysplasia (23.4 years).
For all the cases , 48% were isolated cerebral anomalies, 25% were classified as multiple congenital anomalies, 18% had an associated chromosomal anomaly (6% had Patau syndrome) and for 9% a syndrome was diagnosed ( Table 3 ). The most common associated anomalies were congenital heart defects (CHDs; 9%) and septal defects (ASD and VSD) were the most frequent CHDs. Cases with arhinencephaly or holoprosencephaly were more likely to have a chromosomal anomaly (46% and 36% respectively),
particularly Patau syndrome (33% and 24% respectively). In contrast, cases with septo-optic dysplasia, megalencephaly or cerebral cysts were more likely to be isolated cerebral anomalies (72%, 71% and 67% respectively). The most common genetic syndromes reported were Joubert syndrome (23 cases) and
Aicardi syndrome (13 cases "other reduction deformities of the brain" by 2.8% (0.5% to 5.0%). These significant increases in prevalence remained after adjusting for increases in prenatal diagnoses and for the length of follow-up in the registries
DISCUSSION
The overall prevalence (adjusted for under-reporting) of major congenital cerebral anomalies in Europe from 2005-2014 was 9.8 (95%CI: 8.5 -11.2) per 10,000 births. The prevalence of non-genetic, nonchromosomal anomalies of corpus callosum and of other reduction defects of brain significantly increased, while the prevalences of the other cerebral anomalies were stable. The increases may be due to increased prenatal diagnosis as if cerebral anomalies are not diagnosed prenatally, they may not be diagnosed for several years of age until they emerge in relation to the diagnosis of developmental problems or cerebral palsy [16] .
Our adjusted prevalence for corpus callosum anomalies of 3.3 (95%CI: 2.72 -3.82 ) per 10,000 births with 66% LBs was consistent with two other smaller studies of 38 and 630 cases which did not include fetal losses or TOPFAs [20, 21] . The study from California 1983-2003 [21] showed a prevalence of corpus callosum anomalies 1.8 per 10,000 births and the study from Hungary from 1992-2006 showed a prevalence of 2.05 per 10,000 livebirths [20] . The Californian study found 17% of cases had a chromosomal anomaly similar to the 16% in our study) [21] . The increased risk of preterm birth was also observed in our study [21] .
The adjusted prevalence of holoprosencephaly was 1.6 (95%CI: 1.4 -1.8) per 10,000 births. A literature review including 21 studies found that the prevalence of holoprosencephaly varied between 0.5 to 1.5 per 10,000 births [22] . The authors concluded that the differences in prevalence were mainly explained by the inclusion criteria (LBs or all pregnancy outcomes including early TOPFA). These studies also found a higher female rate and a high proportion of chromosomal cases as in our study (63% were female and 36% were chromosomal cases).
Our study showed an adjusted prevalence of megalencephaly of 0.08 (95%CI: 0.05 -0.11) per 10,000 births.
To our knowledge, there are no published prevalence figures for this anomaly. Most case series and reports describe megalencephaly as an isolated anomaly [23] , which is in line with our findings (71% isolated). A study from a tertiary center in the USA described that almost half of their patients with unilateral megalencephaly had an additional syndrome diagnosis [23] . Tinkle et al [23] report a Japanese study that found 11 of 38 patients (29%) had a syndrome diagnosis (Sasaki et al 2000 -in Japanese so not referenced).
In our study, we found a syndrome diagnosis in 16% of cases.
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Our study showed an adjusted prevalence of arhinencephaly of 0.04 (95%CI: 0.01 -0.07) per 10,000 births.
The only study we identified reported a prevalence of arhinencephaly of 0.14 (95%CI : 0.06 -0.25) per 10,000 births in Atlanta [24] and included only 10 cases, while our study included 46 cases.
The prevalence of our remaining three groups (cerebral cysts (Q046), other specified cerebral anomalies (Q048) and unspecified cerebral anomalies (Q049)) is more heterogeneous and therefore difficult to compare with other studies. Cases with congenital cerebral cysts were mainly liveborn (81%), mainly nongenetic (87%) and half of the cases were diagnosed prenatally. Some cases coded Q048 had the written text description "ventriculomegaly". The EUROCAT definition of hydrocephaly (ICD10 codes in Q03) is a size of the lateral ventricles at 15 mm or more. Cases with an unspecified size of the lateral ventricles or a size at 10-14 mm may have been reported to EUROCAT with the code Q048 for other specified cerebral anomalies. Less than half of the cases reported with unspecified cerebral anomaly were liveborn, indicating the severity of the anomalies but lack of diagnostic details in the EUROCAT registries.
The association between prevalence and prenatal detection rate explains part of the European heterogeneity in the prevalence of cerebral anomalies. In addition, Fetal MRI may be used more frequently in some areas and may increase the detection rate [25] . However, under-ascertainment of cases by the registry may also explain the very low prevalence in some registries. In other registries, there may be overreporting of minor anomalies seen on cerebral imaging or by reporting cerebral injuries after preterm birth or birth asphyxia using ICD codes from the congenital anomaly chapter. The diagnosis of reduction defect of the cerebellum, often with the written text "small cerebellum" was mainly reported by the English registries and there may be different diagnostic criteria for reporting this anomaly. For some cerebral anomalies, in particular reduction defects, the critical exposure period includes up to gestational week 18 [26] . If ultrasound screening is performed at an earlier GA cases may be missed.
There was a high rate of TOPFAs for the anomalies included in this study indicating the severity of cerebral anomalies. Overall, 41% of all cases were TOPFA with the highest TOPFA rate found for arhinencephaly (91%) and holoprosencephaly (78%). For anomalies of corpus callosum, the TOPFA rate was 31%, possibly due to more severe cerebral anomalies being present. Counselling and parental decision-making after prenatal diagnosis of anomalies of corpus callosum is difficult [27] . A study has shown that 25-30% of fetuses with a prenatal diagnosis of isolated agenesis of corpus callosum have developmental delays [28] .
However, a recent study on the use of MR Imaging on fetuses with a suspected brain abnormality on ultrasound showed that fetal MRI changed the prognostic information in 20% of the cases [25] .
Strengths and limitations
The strength of our study is it is the largest covering 6.4 million births in Europe. All registries use the same inclusion criteria for major anomalies and the same coding and classification system for congenital anomalies. There may be underreporting of cases in some registries, but this is adjusted for in the method for calculating the European prevalence of specific anomalies (which does assume that all populations are at equal risk of occurrence of the congenital anomalies of interest which may not be the case). There may also be some over-reporting of minor anomalies, reporting of diagnosis related to birth complications or misclassification of congenital hydrocephaly as ventriculomegaly.
CONCLUSIONS.
Our study provides background prevalence information in the time period before the outbreak of the Zika virus . During this period increasing prevalence was reported due to better prenatal detection.
Heterogeneity in prevalence between regions of Europe may be explained by differences in the prenatal diagnoses and by underreporting of major anomalies in some registries and reporting of minor anomalies as major in other registries.
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